INDP News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$379.7M

Volume

492.74K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. StockholdersAbbott Cooper PLLC is investigating potential fiduciary duty violations by the board of Indaptus Therapeutics in connection with a private placement of preferred stock. The investigation targets stockholders who held shares prior to December 22, 2025.GlobeNewswire Inc. · Jun 18, 2026

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025Indaptus Therapeutics, a clinical-stage biotechnology company, highlights its accomplishments in 2024 and outlines its strategic goals for 2025, including the launch of a combination trial with BeiGene's tislelizumab and the expansion of its Decoy20 clinical trial.GlobeNewswire Inc. · Jan 8, 2025

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual MeetingIndaptus Therapeutics presented positive interim safety data from a Phase 1 trial of its lead compound Decoy20, which showed an acceptable safety profile and signs of anti-tumor activity. The company plans to combine Decoy20 with a PD-1 inhibitor in a new cohort.GlobeNewswire Inc. · Nov 7, 2024

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateCompany to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20GlobeNewswire Inc. · May 8, 2024

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingResults Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and Indirectly Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and IndirectlyGlobeNewswire Inc. · Apr 11, 2024

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingData demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responsesGlobeNewswire Inc. · Mar 25, 2024

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate update.GlobeNewswire Inc. · Mar 13, 2024

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohortGlobeNewswire Inc. · Mar 4, 2024

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionShares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. Butterfly Network posted GAAP loss of 21 cents per share versus market estimates for a loss of 14 cents per share. The company’s quarterly sales came in at sales came in $16.52 million versus estimates of $15.35 million. Butterfly Network shares dipped 21.7% to $1.1588 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Enveric Biosciences, Inc. (NASDAQ: ENVB) gained 177.1% to $2.30 after the company announced it has signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of compounds. Societal CDMO, Inc. (NASDAQ: SCTL) shares climbed 132.7% to $1.07 as the company agreed to be acquired by CoreRx, Inc. Volcon, Inc. (NASDAQ: VLCN) gained 55.4% to $1.8802 after surging around 39% on Wednesday. Sidus Space, Inc. (NASDAQ: SIDU) climbed 39.7% to $7.78. Ocean Biomedical, Inc. (NASDAQ: OCEA) gained 36.4% to $2.1008. Ocean Biomedical announced joint venture partner, Virion Therapeutics to present clinical study data at 2024 APASL Global Liver Meeting. Inseego Corp. (NASDAQ: INSG) rose 34.5% to $3.00. Vertex, Inc. (NASDAQ: VERX) jumped 29.8% to $32.97 after the company reported better-than-expected fourth-quarter results and issued strong FY24 guidance. iHeartMedia, Inc. (NASDAQ: IHRT) rose 29.1% to $2.93 following fourth-quarter results. Agrify Corporation (NASDAQ: AGFY) gained 27% to $0.6161. Agrify announced a $3.4 million sales order from New Jersey woman-owned business HarvestWorks Farm. Renalytix Plc (NASDAQ: RNLX) climbed 26.5% to $1.05 after the company announced that effective Mar. 1, the US approved adding the company's kidneyintelX.dkd to its 10-year Governmentwide Acquisition Contract. Tutor Perini Corporation (NYSE: TPC) gained 26% to $11.64 following fourth-quarter results. Bright Scholar Education Holdings Limited (NYSE: BEDU) gained 25.3% to $2.3178. C3.ai, Inc. (NYSE: AI) shares rose 24.6% to $37.00 after the company reported better-than-expected third-quarter financial results. Sterling Check Corp. (NASDAQ: STER) jumped 24.6% to $15.49 after the company agreed to be acquired by First Advantage for approximately $2.2 billion, including outstanding debt. Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) gained 24% to $2.00. Adial Pharmaceuticals was awarded a new patent covering AD04 for the potential treatment of opioid use disorder. Revance Therapeutics, Inc. (NASDAQ: RVNC) jumped 24% to $7.02 after the company reported better-than-expected quarterly financial results. Latham Group, Inc. (NASDAQ: SWIM) climbed 22.8% to $3.36. Avidity Biosciences, Inc. (NASDAQ: RNA) jumped 22.5% to $18.70. Avidity Biosciences announced an oversubscribed $400 million private placement. Pure Storage, Inc. (NYSE: PSTG) rose 21.9% to $51.35 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance above estimates. ...Benzinga · Feb 29, 2024

Why Okta Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving PremarketShares of Okta, Inc. (NASDAQ: OKTA) shares rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued strong guidance. Okta reported quarterly earnings of 63 cents per share which beat the analyst consensus estimate of 51 cents. Quarterly sales came in at $605 million which beat the analyst consensus estimate of $587.5 million, according to data from Benzinga Pro. Okta shares jumped 23.6% to $107.90 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Volcon, Inc. (NASDAQ: VLCN) gained 138% to $2.88 in pre-market trading after surging around 39% on Wednesday. Societal CDMO, Inc. (NASDAQ: SCTL) shares rose 134.7% to $1.08 in pre-market trading as the company agreed to be acquired by CoreRx, Inc. J-Long Group Limited (NASDAQ: JL) shares surged 38.1% to $17.67 in pre-market trading after dipping over 20% on Wednesday. Voyager Therapeutics, Inc. (NASDAQ: VYGR) gained 24.4% to $11.16 in pre-market trading after the company reported better-than-expected fourth-quarter financial results. Nxu, Inc. (NASDAQ: NXU) ...Benzinga · Feb 29, 2024

INDPIndaptus Therapeutics, Inc. Common Stock

INDP

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any INDP yet.

Related Tickers

Earnings

Mkt Cap

$350.7M

Volume

492.74K

Next Earnings

November 11th